Hypertension adversely impacts the multiple sclerosis (MS) disease course and is more common among Black Americans
Blackpatients with multiple sclerosis have significantly increased odds of uncontrolled hypertension, according to a new study. At the same time, Black Americans have higher odds of receiving anti-hypertensive treatment, according to a new study in Science Direct article.
Hypertension adversely impacts the multiple sclerosis (MS) disease course and is more common among Black Americans. And, while MS used to be predominant among White Americans, recent studies suggest the risk of MS among Blacks is increasing. One retrospective study found a 47% increased risk of MS in Black Americans compared with White Americans, investigators noted.
Additionally, several studies suggest Black Americans experience earlier disability and a more severe disease course, and that social determinants of health and structural racism are likely to play a role in these observations, he added.
In the current study, investigators, led by Devon Conway, M.D., conducted a retrospective study using longitudinal data in the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) registry. Conway is a neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic Foundation.
They found that uncontrolled hypertension was common in MS patients regardless of race, but more common in Black Americans. Out of 10,673 total MS patients (13.5% were Black), Black MS patients had a 31% increased odds of uncontrolled hypertension compared with White patients. After adjustment for relevant covariates, mean systolic blood pressure was 1.84 mmHg higher in Black Americans than White Americans, and mean diastolic blood pressure was 1.28 mmHg higher.
Black Americans were also more likely to be on anti-hypertensive therapy and were exposed to an adjusted average of 0.61 more anti-hypertensive treatments than White Americans. Age, comorbid diabetes mellitus, and comorbid hyperlipidemia were positively associated with use of anti-hypertensive treatments.
In addition, data from the National Health and Nutrition Examination Survey showed that Black Americans with hypertension were more likely to have uncontrolled hypertension than White Americans (57% versus 51%). However, among those with uncontrolled hypertension, Blacks had greater awareness and treatment compared with White Americans.
Black Americans were more likely to have treatment-resistant hypertension compared with White Americans (16.7% versus 11.3%), and among those with treatment resistant hypertension, Blacks were more likely to have refractory hypertension (an extreme phenotype of anti-hypertensive treatment failure) than Whites (4.8% versus 1.2%).
Diabetes Weight Loss Drugs Could be Linked to Reduced Risk of MS, Study Finds
April 12th 2024Drug repurposing has recently emerged as an attractive pathway for developing new treatments due to its relatively fast and cost-efficient trajectory. Because obesity and MS share inflammatory properties, researchers used data from the FDA Adverse Event Reporting System to investigate the association between weight loss-inducing drugs and MS
Read More
Specialty Pharmacist Interventions Result in More Than $150,000 in Cost Avoidance For MS Patients
April 4th 2024Darina Georgieva, Pharm.D., and her colleagues from the department of pharmaceutical services at Vanderbilt University Medical Center, conducted a retrospective observational study to learn the costs avoided through specialty pharmacist interventions for patients at the Vanderbilt MS Clinic. The study results were published in the Journal of Managed Care and Specialty Pharmacy earlier this month.
Read More
Ozanimod Shows Sustained Efficacy in Long-term Study for Multiple Sclerosis Treatment
March 11th 2024Long-term data from the phase 3 DAYBREAK trial affirmed sustained efficacy of ozanimod for relapsing forms of multiple sclerosis, with a high amount of patients who were relapse-free at 6 years.
Read More